Literature DB >> 32437932

Usefulness of bronchoalveolar lavage in the management of patients presenting with lung infiltrates and suspect COVID-19-associated pneumonia: A case report.

Gina Gualano1, Maria Musso2, Silvia Mosti3, Paola Mencarini4, Annelisa Mastrobattista5, Carlo Pareo6, Mauro Zaccarelli7, Paolo Migliorisi8, Pietro Vittozzi9, Alimudin Zumla10, Giuseppe Ippolito11, Fabrizio Palmieri12.   

Abstract

OBJECTIVE: To report a clinical case of a patient with a compatible HRCT scan and two negative SARS-CoV-2 RNA upper respiratory tract specimens but with a confirmed viral infection by BAL (19 days after symptom onset).
METHODS: Revision of a patient's clinical charts with COVID-19 admitted at INMI L. Spallanzani Hospital
RESULTS: Two oropharyngeal swab tests of SARS-CoV-2 by qualitative real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay were performed at admission (17 days from symptoms onset) and a day apart and were found negative. BAL fluid collected 19 days after symptoms onset was positive for SARS-CoV-2.
CONCLUSION: This case highlights importance of clinical suspicion of SARS-CoV-2 infection in diagnosis and infectivity assessment. We suggest collection of BAL fluid when consecutive nasopharyngeal swabs are negative, to confirm or exclude the diagnosis of COVID-19-associated pneumonia. Healthcare workers should perform aerosol-generating procedures in an adequately ventilated room and should wear adequate PPE.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  BAL fluid; COVID-19; Nasopharyngeal swabs; SARS CoV2 pneumonia

Mesh:

Substances:

Year:  2020        PMID: 32437932      PMCID: PMC7211646          DOI: 10.1016/j.ijid.2020.05.027

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


Introduction

In December 2019, a novel coronavirus infection, named severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), emerged in Wuhan, Hubei Province, China which the World Health Organization (WHO) has named 2019 novel coronavirus disease (COVID-19) [1]. The clinical spectrum of SARS-CoV-2 infection appears to be wide, encompassing asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure and even death [2]. It is a highly infectious disease and currently person-to-person transmission is the main source of infection; many unknowns remain regarding the virulence/pathogenicity, the effectiveness of different modes of transmission, the infectivity during the incubation period and during recovery, the impact of individual or population-based preventive measures [3]. The approach to initial management should focus on early recognition of suspect cases, immediate isolation, and institution of infection control measures [4]. Viral nucleic acid detection by reverse transcription PCR (RT-PCR) is regarded as the gold standard technique for the etiological diagnosis of COVID-19 [5]. For initial diagnostic testing for COVID-19, collecting and testing an upper respiratory specimen is recommended. Nasopharyngeal and oropharyngeal swabs are the preferred choice for swab-based SARS-CoV-2 testing. The induction of sputum is not recommended and aspirate or bronchoalveolar lavage sample should be collected and tested only when it is clinically required [6]. Here we report a case with CT scan images suggestive for COVID-19-associated pneumonia with negative oropharyngeal swabs test for SARS-CoV-2 RNA at hospital admission and confirmation after BAL positivity.

Case presentation

A 72-year-old female patient was admitted to L. Spallanzani Institute in Rome, compelling a 17-day history of fever (up to 39°C), cough and sore throat. She has been treated with amoxi-clavulanic acid and then with ceftriaxone before admission, with no clinical response. She denied travel to China or to northern Regions of Italy, contacts with symptomatic patients in the past fourteen days before hospitalization. She denied experiencing shortness of breath, chest pain cough and any gastrointestinal symptoms (no nausea, vomiting, or diarrhea). Her past medical history included hypertension, past breast and thyroid cancer with thyroid hormone replacement. High-resolution computed tomography (HRCT) of the chest documented images of multiple patchy ground glass opacities in bilateral sub pleural areas (Fig. 1 ). Given chest HRCT findings, suggestive for COVID-19 pneumonia, she was admitted an airborne-isolation room.
Fig. 1

Chest CT images showing bilateral ground glass opacities.

Chest CT images showing bilateral ground glass opacities. On admission, physical examination revealed normal vital signs, with body temperature 38°C and oxygen saturation of 97% in ambient air. Lung auscultation was normal. Arterial blood gas analysis showed mild respiratory impairment with arterial oxygen tension (PaO2) 67 mmHg in air breathing and oxygenation index (P/F ratio) of 323 mmHg. Her white blood cell count was 8.75×109 cell/L, lymphocyte count was 1.15×109 cell/L, C-reactive protein level was 13.85 mg/L (normal range <1 mg/L). Liver function, renal function, myocardial enzymes and electrolytes were normal (Annex 1). Legionella and Pneumococcal urinary antigen, Chlamydia and Mycoplasma serology were negative. Two oropharyngeal swab tested negative for SARS-CoV-2 by qualitative real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) at hospital admission (17 days from symptoms onset) and a day apart. According to chest HRCT findings and persistent fever, a Bronchoscopy was performed (19 days from symptoms onset) with RT-PCR for SARS-CoV-2 positive result in BAL fluid. The patient has been treated according to local protocol at that time, with symptomatic and antiviral therapy including lopinavir/ritonavir. Seven days after admission patient’s respiratory symptoms improved and she was discharged in community after collection of two negative oropharyngeal swab tests.

Discussion

We describe the case of a patient with a very high index of suspicion for COVID-19-associated pneumonia in whom the research of SARS-CoV-2 RNA was negative in upper respiratory tract specimen, and detectable in BAL fluid. The possibility of COVID-19 should be considered primarily in patients with fever and lower respiratory tract symptoms, who resided in or have recently (within the prior 14 days), traveled to high incidence regions or who have had recent (within the prior 14 days) close contact with a confirmed or suspected case of COVID-19 [4]. Even if pneumonia appears to be the most frequent serious manifestation of infection, patients could be falsely negative if tested only with upper respiratory tract samples [7]. Over the course of the infection, the virus has been identified in respiratory tract specimens 1-2 days before the onset of symptoms and it can persist for 7-12 days in moderate cases and up to 2 weeks in severe cases [8]. Collection of specimens from upper respiratory mucosa by nose and throat swabs is a procedure used for the diagnosis of Covid-19 [9]. Lillie PJ et al reported discordance between nose and throat samples in a UK patient, highlighting the need to sample from both areas [10]. In the presence of a suspicion of COVID-19-associated pneumonia, false-negative results could hinder the prevention and control of the epidemic, particularly when this test plays a key role in deciding the necessity for continued isolated medical observation or discharge. Screening based on symptoms and CT scan, even in the best case scenario, is not sensitive [11]. According to WHO guidelines, in patient with suspected COVID-19-associated pneumonia, negative specimens from the upper respiratory tract do not exclude the diagnosis, and additional lower respiratory tract samples are recommended [12]. Sputum induction demonstrated more helpful than throat swabs for the detection of SARS-CoV-2 RNA in convalescent patients [13]. Although sampling from the lower respiratory tract is recommended by WHO, these procedures potentially generate aerosols with an increased risk of transmission and must be performed with strict airborne precautions, minimizing exposure of health care workers [14]. Here we report the case of a patient with a compatible HRTC scan and two negative SARS-CoV-2 RNA from upper respiratory tract specimens, but with a confirmed viral infection in BAL (19 days after symptom onset). The detection of SARS-CoV-2 RNA in lower respiratory tract samples after two negative nasopharyngeal may reflect SARS-CoV-2 persistence in lower respiratory tract. This case highlights importance of clinical suspicion of SARS-CoV-2 RNA for diagnosis and infectivity assessment. If the patient’s travel or exposure history or symptoms and radiological imaging suggest possible COVID-19-associated pneumonia, each effort should be done to achieve etiological diagnosis of the disease, also for infectiousness consequences. RT-PCR for SARS-CoV-2 in lower respiratory samples (induced sputum or BAL) may increase sensitivity in cases with clinical and radiological suspicion of COVID-19- pneumonia. During ongoing epidemic in presence of symptoms and radiological findings compatible with suspected COVID-19 pneumonia, negative upper respiratory tract samples does not ever exclude the diagnosis, and additional lower respiratory tract samples are recommended. It should be underlined that bronchoscopy, and induced sputum, are aerosol-generating procedures and have been associated with an increased risk of nosocomial transmission of coronaviruses. Healthcare workers, possibly trained and dedicated personnel, should perform these procedures in an adequately ventilated room and should wear adequate PPE.

Consent for publication

Written informed consent was obtained from patient for this paper to be published. A copy of the written consent is available for review by the Editor of this journal.

Authors contributions

GG and FP conceived the study. MM, GG and FP wrote the paper. MM, SM, PM, PV and MZ supplied the clinical data. GG, MM, SM, PM, MZ, CP, AM and FP evaluated and treated the patients. GI and AZ reviewed the paper. All authors reviewed and approved the final version of the paper submitted to the journal.

Funding

This work was supported by funding from Italian Ministry of Health, grant Ricerca Corrente IRCCS, Research program no. 4 Tuberculosis. The funder had no role in study design, data collection, analysis and interpretation, and preparation of the manuscript.

Ethical approval

The patient provided written informed consent to the utilization of anonymous clinical data for research purpose

Conflicts of Interest

All authors declare no conflict of interest
  9 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.

Authors:  Tao Ai; Zhenlu Yang; Hongyan Hou; Chenao Zhan; Chong Chen; Wenzhi Lv; Qian Tao; Ziyong Sun; Liming Xia
Journal:  Radiology       Date:  2020-02-26       Impact factor: 11.105

Review 3.  Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.

Authors:  Jason Phua; Li Weng; Lowell Ling; Moritoki Egi; Chae-Man Lim; Jigeeshu Vasishtha Divatia; Babu Raja Shrestha; Yaseen M Arabi; Jensen Ng; Charles D Gomersall; Masaji Nishimura; Younsuck Koh; Bin Du
Journal:  Lancet Respir Med       Date:  2020-04-06       Impact factor: 30.700

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  Updated rapid risk assessment from ECDC on the outbreak of COVID-19: increased transmission globally.

Authors: 
Journal:  Euro Surveill       Date:  2020-03

6.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

7.  Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission.

Authors:  Patrick J Lillie; Anda Samson; Ang Li; Kate Adams; Richard Capstick; Gavin D Barlow; Nicholas Easom; Eve Hamilton; Peter J Moss; Adam Evans; Monica Ivan; Yusri Taha; Christopher J A Duncan; Matthias L Schmid
Journal:  J Infect       Date:  2020-02-28       Impact factor: 6.072

8.  Viral dynamics in mild and severe cases of COVID-19.

Authors:  Yang Liu; Li-Meng Yan; Lagen Wan; Tian-Xin Xiang; Aiping Le; Jia-Ming Liu; Malik Peiris; Leo L M Poon; Wei Zhang
Journal:  Lancet Infect Dis       Date:  2020-03-19       Impact factor: 25.071

Review 9.  Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures.

Authors:  Yixuan Wang; Yuyi Wang; Yan Chen; Qingsong Qin
Journal:  J Med Virol       Date:  2020-03-29       Impact factor: 20.693

  9 in total
  13 in total

1.  Comprehensive evaluation of bronchoalveolar lavage from patients with severe COVID-19 and correlation with clinical outcomes.

Authors:  Ian Gelarden; Jessica Nguyen; Juehua Gao; Qing Chen; Luisa Morales-Nebreda; Richard Wunderink; Lin Li; Joan S Chmiel; MaryAnn Hrisinko; Laura Marszalek; Sumaiya Momnani; Pinal Patel; Ricardo Sumugod; Qi Chao; Lawrence J Jennings; Teresa R Zembower; Peng Ji; Yi-Hua Chen
Journal:  Hum Pathol       Date:  2021-04-24       Impact factor: 3.526

2.  Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis.

Authors:  Gauruv Bose; Kristin Galetta
Journal:  Mult Scler Relat Disord       Date:  2021-03-25       Impact factor: 4.808

3.  Coronavirus Disease 2019 Test Correlation Between Nasopharyngeal Swab and BAL in Asymptomatic Patients.

Authors:  Jiwoon Chang; Kai E Swenson; Arthur Sung; Harmeet Bedi
Journal:  Chest       Date:  2020-11-17       Impact factor: 9.410

4.  Role of the Bronchoalveolar Lavage in Noncritically Ill Patients during the SARS-CoV-2 Epidemic.

Authors:  Olivier Taton; Emmanuelle Papleux; Benjamin Bondue; Christiane Knoop; Sébastien Van Laethem; Alain Bauler; Delphine Martiny; Isabel Montesinos; Marie-Luce Delforge; Kahina Elmaouhab; Dimitri Leduc
Journal:  Pulm Med       Date:  2020-12-17

5.  Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing.

Authors:  Daniel R Kaul; Andrew L Valesano; Joshua G Petrie; Rommel Sagana; Dennis Lyu; Jules Lin; Emily Stoneman; Lane M Smith; Paul Lephart; Adam S Lauring
Journal:  Am J Transplant       Date:  2021-03-15       Impact factor: 9.369

6.  Risk factors for delayed negative conversion of SARS-CoV-2 in patients with COVID-19 pneumonia: a retrospective cohort study.

Authors:  Pingzheng Mo; Liping Deng; Xiaoping Liu; Shicheng Gao; Ke Liang; Mingqi Luo; Tielong Chen; Shihui Song; Zhiyong Ma; Xiaoping Chen; Junli Fan; Fan Wang; Yong Xiong; Yongxi Zhang
Journal:  Epidemiol Infect       Date:  2020-12-01       Impact factor: 2.451

7.  Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 test for bronchoalveolar lavage.

Authors:  Tung Phan; Ashley Mays; Melissa McCullough; Alan Wells
Journal:  J Clin Virol Plus       Date:  2022-02-19

8.  COVID-19 Infection Negative in Nasopharyngeal Swabs but Suspected in Computed Tomography and Confirmed in Bronchoalveolar Lavage Material.

Authors:  Robert Chrzan; Tadeusz Popiela; Maciej Małecki; Jan Skupień; Amira Bryll; Anna Grochowska
Journal:  Case Rep Infect Dis       Date:  2021-04-20

Review 9.  Salivary diagnostics of the novel coronavirus SARS-CoV-2 (COVID-19).

Authors:  Evangelia Michailidou; Athanasios Poulopoulos; Georgios Tzimagiorgis
Journal:  Oral Dis       Date:  2020-12-04       Impact factor: 4.068

10.  Pediatric Rigid Bronchoscopy for Tracheobronchial Foreign Bodies in Covid Times: Short Personal Experience.

Authors:  Suhail Amin Patigaroo; Sajad Majid Qazi; Rauf Ahmad; Manzoor A Latoo; Nisar Husain Dar; Showkat A Showkat; Ahsan Ali
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2020-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.